A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.

A A Chiappori,T Kolevska,D R Spigel,S Hager,M Rarick,S Gadgeel,N Blais,J Von Pawel,L Hart,M Reck,E Bassett,B Burington,J H Schiller

Annals of Oncology（2015）

Cited 125|Views12

No score

Abstract

Imetelstat, a novel telomerase inhibitor, failed to improve significantly median PFS and OS as maintenance therapy (±bevacizumab) in advanced NSCLC. Telomere length (TL) biomarker results were consistent with the hypothesis that telomerase inhibition is of greater benefit to patients with tumors possessing shorter telomeres; the patients with shorter TL had a trend toward longer median PFS and OS.

Translated text

Key words

non-small-cell lung cancer,biomarker,imetelstat

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined